{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:43:31Z","timestamp":1773117811436,"version":"3.50.1"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,5,5]]},"DOI":"10.18632\/oncotarget.27516","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T14:24:11Z","timestamp":1588688651000},"page":"1576-1589","source":"Crossref","is-referenced-by-count":9,"title":["The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma"],"prefix":"10.18632","volume":"11","author":[{"given":"Cristina","family":"Kinahan","sequence":"first","affiliation":[{"name":"Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Mangone","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Scotto","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Visentin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Marchi","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen A.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Mellqvist","year":"2016","journal-title":"Leukemia"},{"key":"2","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Bergsagel","year":"2012","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Tubio","year":"2014","journal-title":"Nat Commun"},{"key":"4","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"key":"5","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1200\/JCO.2010.34.0760","article-title":"Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma","volume":"29","author":"Richardson","year":"2011","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin\u2019s lymphoma","volume":"12","author":"O\u2019Connor","year":"2006","journal-title":"Clin Cancer Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00280-014-2441-9","article-title":"The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells","volume":"73","author":"Goldman","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/CMR.S10043","article-title":"Cancer chemotherapy: targeting folic acid synthesis","volume":"2","author":"Joerger","year":"2010","journal-title":"Cancer Manag Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib inandmodels of T-cell lymphoid malignancies","volume":"16","author":"O\u2019Connor","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00280-009-0954-4","article-title":"Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates inandmodels of human cancers","volume":"64","author":"Saunders","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s002800050823","article-title":"A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice","volume":"42","author":"Piper","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"12","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1021\/jm00067a020","article-title":"Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin","volume":"36","author":"Sirotnak","year":"1993","journal-title":"J Med Chem"},{"key":"13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00280-013-2231-9","article-title":"The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor","volume":"72","author":"Goldman","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.bjc.6606063","article-title":"Single agent and combination studies of pralatrexate and molecular correlates of sensitivity","volume":"104","author":"Raymond","year":"2011","journal-title":"Br J Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Moore","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Marchi","year":"2018","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.hoc.2016.11.002","article-title":"Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"31","author":"O\u2019Connor","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"18","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma","volume":"21","author":"Amengual","year":"2015","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"O\u2019Connor","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"Zelenetz","year":"2007","journal-title":"Br J Haematol"},{"key":"21","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1182\/blood-2009-03-210989","article-title":"Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma\/leukemia causing skin erosions","volume":"113","author":"Zain","year":"2009","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"Furman","year":"2011","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Duvic","year":"2012","journal-title":"Blood"},{"key":"24","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"Sirotnak","year":"2009","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0092-8674(76)90168-9","article-title":"Elevated dihydrofolate reductase messenger RNA levels in methotrexate-resistant BHK cells","volume":"7","author":"Littlefield","year":"1976","journal-title":"Cell"},{"key":"26","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/0277-5379(91)90096-V","article-title":"Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedules","volume":"27","author":"Hordijk","year":"1991","journal-title":"Eur J Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ijc.10829","article-title":"Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines","volume":"103","author":"Assaraf","year":"2003","journal-title":"Int J Cancer"},{"key":"28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/978-1-4615-4811-9_59","article-title":"Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation","volume":"457","author":"Bertino","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9258(17)42301-5","article-title":"A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells","volume":"269","author":"Cowan","year":"1994","journal-title":"J Biol Chem"},{"key":"30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood.V89.3.1013","article-title":"Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression","volume":"89","author":"Bertino","year":"1997","journal-title":"Blood"},{"key":"31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1101\/SQB.1978.042.01.067","article-title":"Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells","volume":"42","author":"Bertino","year":"1978","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.1984.2.1.16","article-title":"Resistance to methotrexate due to gene amplification in a patient with acute leukemia","volume":"2","author":"Bertino","year":"1984","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1016\/S0021-9258(18)94097-4","article-title":"Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug","volume":"264","author":"Bertino","year":"1989","journal-title":"J Biol Chem"},{"key":"34","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1182\/blood.V89.7.2494","article-title":"Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line","volume":"89","author":"Moscow","year":"1997","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4143\/crt.2010.42.3.163","article-title":"Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicity","volume":"42","author":"Kang","year":"2010","journal-title":"Cancer Res Treat"},{"key":"36","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4161\/cc.3.10.1196","article-title":"Mcl-1 regulation and its role in multiple myeloma","volume":"3","author":"Anderson","year":"2004","journal-title":"Cell Cycle"},{"key":"37","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1158\/1078-0432.CCR-14-1437","article-title":"miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma","volume":"21","author":"Chang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/sj.leu.2404599","article-title":"Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis","volume":"21","author":"Pandiella","year":"2007","journal-title":"Leukemia"},{"key":"39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nm.2112","article-title":"Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity","volume":"16","author":"Mitsiades","year":"2010","journal-title":"Nat Med"},{"key":"40","first-page":"597","article-title":"The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone","volume":"26","author":"Epstein","year":"1998","journal-title":"Exp Hematol"},{"key":"41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","article-title":"Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells","volume":"10","author":"Jove","year":"1999","journal-title":"Immunity"},{"key":"42","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1038\/sj.onc.1204465","article-title":"Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations","volume":"20","author":"Neri","year":"2001","journal-title":"Oncogene"},{"key":"43","doi-asserted-by":"publisher","first-page":"19065","DOI":"10.1074\/jbc.273.30.19065","article-title":"A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function","volume":"273","author":"Goldman","year":"1998","journal-title":"J Biol Chem"},{"key":"44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev-physiol-020911-153251","article-title":"The intestinal absorption of folates","volume":"76","author":"Goldman","year":"2014","journal-title":"Annu Rev Physiol"},{"key":"45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.hoc.2012.02.002","article-title":"The antifolates","volume":"26","author":"Goldman","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"46","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1038\/s41598-017-08348-5","article-title":"STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer","volume":"7","author":"Horn","year":"2017","journal-title":"Sci Rep"},{"key":"47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bbrc.2017.07.067","article-title":"Inhibition of IL-6\/STAT3 signaling in human cancer cells using Evista","volume":"491","author":"Lin","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"48","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1158\/1078-0432.CCR-18-2402","article-title":"Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth","volume":"25","author":"Biyashev","year":"2019","journal-title":"Clin Cancer Res"},{"key":"49","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-10-1820","article-title":"MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin","volume":"17","author":"Jayabalan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","article-title":"The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation","volume":"106","author":"Cho","year":"2005","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:34:09Z","timestamp":1615595649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":50,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,5,5]]}},"alternative-id":["27516","32405334"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27516","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]}}}